Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fel-O-Vax FIV
- Development stage
- Unknown
- Lead developer
- Fort Dodge Laboratories
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Fel-O-Vax FIV is an inactivated, adjuvanted vaccine developed to aid in the prevention of infection by the Feline Immunodeficiency Virus (FIV) in healthy cats 8 weeks of age or older. The vaccine is unique for its dual-subtype composition, containing inactivated whole viruses and infected cells from both FIV subtype A (Petaluma strain) and subtype D (Shizuoka strain). This formulation is designed to confer cross-protective immunity against various global FIV subtypes, including the prevalent subtype B. The vaccine stimulates both humoral and cellular immune responses to protect against the immunosuppressive effects of this lentivirus. Originally developed by Fort Dodge Animal Health, the vaccine's ownership transitioned through Pfizer and Boehringer Ingelheim before being acquired by Elanco as part of its U.S. companion animal vaccine portfolio.
- Brand names
- Fel-O-Vax FIV
- Other names
- Feline Immunodeficiency Virus Vaccine, Killed VirusFeline immunodeficiency virus vaccine
Beyond the preview
Go deeper on Fel-O-Vax FIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fel-O-Vax FIV.